Exercise and Acarbose in Type 2 Diabetes

NCT ID: NCT01244971

Last Updated: 2010-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

62 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to investigate the impact of exercise training, Acarbose, and the combination of exercise and Acarbose on glycemic control, body composition, insulin sensitivity and other cardiovascular risk markers in type 2 diabetes. Further, muscle biopsies will be obtain to study gene expression. Our hypothesis is that the combination therapy will be superior to monotherapy with exercise or Acarbose.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acarbose

Group Type ACTIVE_COMPARATOR

Acarbose

Intervention Type DRUG

100mg, 3 times daily

Exercise

Group Type ACTIVE_COMPARATOR

Exercise

Intervention Type BEHAVIORAL

Moderate combined exercise, 50 minutes 3 times per week

Exercise + Acarbose

Group Type EXPERIMENTAL

Exercise + Acarbose

Intervention Type OTHER

See respective monotherapy description

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acarbose

100mg, 3 times daily

Intervention Type DRUG

Exercise

Moderate combined exercise, 50 minutes 3 times per week

Intervention Type BEHAVIORAL

Exercise + Acarbose

See respective monotherapy description

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

\-
Minimum Eligible Age

45 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

The Swedish Research Council

OTHER_GOV

Sponsor Role collaborator

Bayer

INDUSTRY

Sponsor Role collaborator

Karolinska Institutet

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Suad Efendic, Professor

Role: STUDY_CHAIR

Dpt of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Enheten för Metabol Kontroll, Endokrinkliniken, Karolinska University Hospital

Stockholm, Stockholm County, Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

References

Explore related publications, articles, or registry entries linked to this study.

Wagner H, Degerblad M, Thorell A, Nygren J, Stahle A, Kuhl J, Brismar TB, Ohrvik J, Efendic S, Bavenholm PN. Combined treatment with exercise training and acarbose improves metabolic control and cardiovascular risk factor profile in subjects with mild type 2 diabetes. Diabetes Care. 2006 Jul;29(7):1471-7. doi: 10.2337/dc05-2513.

Reference Type RESULT
PMID: 16801564 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

DNR 03-539

Identifier Type: -

Identifier Source: org_study_id